On this page
Von Hippel-Lindau syndrome
This autosomal dominant disorder arises from pathogenic variants in VHL and typically causes benign and malignant growths in the central nervous system, eyes, kidneys, pancreas and adrenal glands. Early detection through surveillance programmes can significantly improve outcomes for affected individuals.
Available at Jeen Health
Clinical tests that include this
Overview
Von Hippel-Lindau syndrome affects approximately 1 in 36,000 people in the UK, making it a relatively rare inherited cancer predisposition condition. The disorder is named after the physicians who first characterised it in the early 20th century. Individuals with this syndrome face an elevated risk of developing various tumours and cysts, some of which may be cancerous, typically appearing between adolescence and middle age.
The hallmark features include haemangioblastomas (blood vessel tumours) in the brain, spinal cord and retina, clear cell renal cell carcinoma (kidney cancer), phaeochromocytomas (adrenal gland tumours), and pancreatic lesions. Not everyone with Von Hippel-Lindau syndrome develops all possible complications, and the severity varies considerably between families and individuals. Because these tumours can appear in multiple locations and at different times throughout life, coordinated surveillance and management through specialist NHS services is essential for maintaining quality of life and preventing serious complications.
Symptoms & clinical features
Clinical features of Von Hippel-Lindau syndrome often begin to emerge in young adulthood, though some manifestations may appear during childhood or later in life. Haemangioblastomas in the central nervous system can cause headaches, balance problems, dizziness or weakness depending on their location. When these blood vessel tumours develop in the retina, they may lead to vision changes, floaters or progressive vision loss if left untreated. Many individuals first come to medical attention because of eye problems detected during routine examination.
Kidney manifestations include both benign cysts and clear cell renal cell carcinomas, which may cause blood in the urine, flank pain or high blood pressure, though many kidney lesions remain asymptomatic until detected on surveillance imaging. Phaeochromocytomas produce excess adrenaline and related hormones, leading to episodes of rapid heartbeat, headaches, sweating and high blood pressure. Pancreatic involvement may include cysts or neuroendocrine tumours, which are usually asymptomatic but occasionally cause abdominal discomfort. The variable presentation means that some people experience significant symptoms whilst others have lesions discovered incidentally during screening programmes recommended for those with a known genetic diagnosis.
Video: Is cancer in your genes?
Affected organs
The eyes, brain, spinal cord, kidneys, pancreas and adrenal glands represent the organs most frequently affected in Von Hippel-Lindau syndrome. Retinal haemangioblastomas can compromise vision if they cause retinal detachment or bleeding within the eye. Central nervous system haemangioblastomas, particularly those in the cerebellum or brainstem, may interfere with coordination, balance and other neurological functions. The kidneys face dual risks from both cyst formation and malignant transformation to clear cell carcinoma, with renal cell cancer being a leading cause of mortality in this condition.
Pancreatic lesions range from simple cysts to serous cystadenomas and pancreatic neuroendocrine tumours, though these are typically less aggressive than the pancreatic cancers seen in the general population. Phaeochromocytomas arising in the adrenal glands can produce dangerous elevations in blood pressure and cardiovascular complications if unrecognised. Less commonly, individuals may develop endolymphatic sac tumours affecting hearing, or epididymal cystadenomas in males. The multi-system nature of this syndrome necessitates a coordinated approach to surveillance and management across multiple medical specialties.
Risks & severity
The lifetime risk of developing at least one manifestation of Von Hippel-Lindau syndrome is very high in individuals carrying a pathogenic variant in VHL, though the specific complications and their timing vary considerably. Retinal haemangioblastomas occur commonly in affected individuals, often representing the earliest detectable sign of the condition. Central nervous system haemangioblastomas develop frequently in people with the syndrome, typically appearing between the second and fourth decades of life. Clear cell renal cell carcinoma affects a substantial proportion of individuals, with kidney cancer representing the most common cause of mortality in Von Hippel-Lindau syndrome.
Phaeochromocytomas occur less commonly in affected people, though the frequency varies between different VHL variant types. The severity spectrum is broad - some individuals experience their first tumour in childhood whilst others remain asymptomatic into middle age. Families may share similar patterns of organ involvement due to specific variants, though variability exists even within the same family. With appropriate surveillance and timely intervention, many tumours can be detected early when treatment is most effective, substantially improving long-term outcomes and life expectancy compared to historical cohorts before modern screening protocols were established.
Genetic causes
Von Hippel-Lindau syndrome results from pathogenic variants in VHL, located on chromosome 3. The normal protein encoded by this gene contributes to a cellular complex known as VCB-CUL2. This complex tags particular proteins for destruction when cells no longer require them. VHL's involvement in regulating hypoxia-inducible factors proves especially important - these molecules help cells respond to low oxygen availability. Under normal oxygen conditions, VHL directs breakdown of hypoxia-inducible factors, keeping their levels appropriately controlled.
Pathogenic changes in VHL disrupt this regulatory function, allowing hypoxia-inducible factors to accumulate even when oxygen supply is adequate. Excessive amounts of these factors trigger overproduction of growth signals that stimulate blood vessel formation and cellular proliferation. This creates conditions favouring tumour development, particularly in tissues with rich vascular networks, which helps explain the prominence of haemangioblastomas and highly vascular kidney cancers in this syndrome. The unaffected VHL copy on the paired chromosome typically offers some protective function. However, when this second copy also becomes inactivated within individual cells - a process termed loss of heterozygosity - tumour formation accelerates. Different variant types, such as complete deletions versus single nucleotide changes, correlate with somewhat distinct clinical patterns, particularly regarding phaeochromocytoma development.
- VHL von Hippel-Lindau tumor suppressorThe VHL gene encodes a tumour suppressor protein that regulates cellular responses to oxygen levels and controls the degradation of proteins involved in blood vessel formation.
Inheritance pattern
Von Hippel-Lindau syndrome follows an autosomal dominant inheritance pattern, meaning a pathogenic variant in just one copy of VHL is sufficient to substantially increase cancer risk. Each child of an affected parent has a 50% chance of inheriting the familial variant and therefore the predisposition to developing syndrome-related tumours. The condition affects males and females equally. Most diagnosed individuals have inherited the variant from a parent, whilst some represent new (de novo) variants arising for the first time in that individual.
Because the condition is dominant, individuals with a VHL pathogenic variant will typically develop at least some manifestations during their lifetime, though the specific organs affected and the age of onset vary even between family members sharing the same variant. Relatives who have not inherited the familial variant face the same cancer risks as the general population. Genetic counselling before or during family planning allows prospective parents to understand reproductive options, including predictive testing of at-risk relatives, prenatal diagnosis and preimplantation genetic testing for those who wish to avoid passing the condition to future generations.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of Von Hippel-Lindau syndrome typically combines clinical findings with genetic testing confirmation. Clinical diagnostic criteria include the presence of characteristic tumours - such as central nervous system or retinal haemangioblastomas, clear cell renal cell carcinoma, phaeochromocytoma or pancreatic neuroendocrine tumour - particularly when multiple tumours occur or when an individual has a family history suggesting the condition. Imaging studies including MRI of the brain and spine, CT or MRI of the abdomen, and ophthalmological examination form essential components of the diagnostic evaluation.
Genetic testing through the NHS Genomic Medicine Service provides definitive diagnosis by identifying pathogenic variants in VHL. Testing is typically arranged through clinical genetics services following referral from oncology, ophthalmology, neurosurgery or other relevant specialties. The appropriate PanelApp panel (R207 - Inherited phaeochromocytoma and paraganglioma, or R210 - Inherited renal cancer) may be used depending on the presenting features. Once a pathogenic variant is confirmed in an affected individual, predictive testing becomes available for at-risk family members, allowing those who have not inherited the variant to discontinue intensive surveillance whilst those who carry it can begin appropriate screening protocols. Genetic counsellors within NHS regional genetics services provide essential support in interpreting test results and understanding implications for the individual and their relatives.
Management & lifestyle
Management of Von Hippel-Lindau syndrome centres on regular surveillance to detect tumours early when treatment is most straightforward and effective, combined with timely intervention for significant lesions. NHS specialist centres with expertise in this condition coordinate care across multiple disciplines. Surveillance protocols typically recommend annual ophthalmological examinations from childhood, regular MRI scanning of the brain and spine beginning in adolescence, and periodic abdominal imaging to monitor the kidneys, pancreas and adrenal glands. The exact surveillance schedule is tailored to individual and family history.
When tumours are detected, treatment decisions balance the risks of intervention against the natural history of each lesion type. Retinal haemangioblastomas may be treated with laser photocoagulation or cryotherapy to preserve vision. Central nervous system haemangioblastomas often require surgical removal when they cause symptoms or show significant growth. For kidney lesions, a nephron-sparing approach is generally preferred given the likelihood of multiple tumours over time - small renal masses may be monitored whilst larger lesions are treated with partial nephrectomy or, in some centres, ablative techniques. Phaeochromocytomas require careful preoperative management followed by surgical removal. Lifestyle modifications are not typically emphasised as primary management strategies, though maintaining overall health supports tolerance of treatments and recovery from procedures. Genetic counselling remains an integral component of care, helping individuals and families navigate screening recommendations, reproductive options and psychosocial aspects of living with an inherited cancer syndrome. Clinical trials investigating novel surveillance methods and targeted therapies may be available through specialist centres.
UK care pathway
Within the NHS, individuals with suspected or confirmed Von Hippel-Lindau syndrome are typically managed through regional genetics centres working alongside specialist multidisciplinary teams. Referral to clinical genetics can be initiated by general practitioners, ophthalmologists, neurologists, urologists, endocrinologists or oncologists when characteristic features are identified. Genetic testing is accessed through the NHS Genomic Medicine Service using relevant rare disease testing panels, with R207 (Inherited phaeochromocytoma and paraganglioma) or R210 (Inherited renal cancer) representing common entry points depending on presentation.
Following genetic confirmation, individuals are enrolled in structured surveillance programmes, often coordinated through specialist inherited cancer or endocrine clinics with experience managing Von Hippel-Lindau syndrome. These services liaise with ophthalmology, neurosurgery, urology, endocrine surgery and interventional radiology as needed. Genetic counsellors provide ongoing support, explaining test results, discussing implications for relatives and facilitating cascade testing within families. Many regions have established care pathways linking local specialists with national expertise centres, ensuring individuals receive evidence-based surveillance and access to clinical trials where appropriate. Patient organisations provide additional resources and peer support for families navigating this lifelong condition.
Frequently asked questions
If I have Von Hippel-Lindau syndrome, will I definitely develop cancer?
Most people with a VHL pathogenic variant will develop at least some tumours during their lifetime, but not all of these are cancerous. Many lesions, such as haemangioblastomas, are benign. Regular surveillance helps detect any changes early when treatment is most effective, substantially improving long-term outcomes.
How often will I need screening if I have this condition?
Surveillance schedules are individualised but typically include annual eye examinations, brain and spine MRI scans every 1-2 years, and abdominal imaging every 1-2 years depending on age and previous findings. Your specialist team will recommend a schedule tailored to your personal and family history.
Can my children be tested for Von Hippel-Lindau syndrome?
Once a pathogenic VHL variant is identified in the family, children can be offered predictive genetic testing. Testing in childhood may be appropriate given that surveillance often begins in the teenage years or earlier, allowing early detection of treatable lesions. Genetic counsellors can discuss the optimal timing for your family.
What happens if a tumour is found during surveillance?
Not all detected tumours require immediate treatment. Small, stable lesions may simply be monitored with repeat imaging, whilst growing or symptomatic tumours are considered for intervention. Treatment options range from laser therapy for eye lesions to surgery for larger tumours, with decisions made by specialist teams considering each tumour's location, size and growth pattern.
Does Von Hippel-Lindau syndrome affect life expectancy?
With modern surveillance and treatment, many individuals with Von Hippel-Lindau syndrome live long, productive lives. Life expectancy has improved considerably with structured screening programmes that detect tumours early. The most significant factor influencing outcomes is engagement with regular monitoring and timely treatment when needed.
References
- Harbi E, Aschner M. Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies. Molecular biology reports. 2025. PMID: 40042715
- Ben-Skowronek I, Kozaczuk S. Von Hippel-Lindau Syndrome. Hormone research in paediatrics. 2015. PMID: 26279462
- Adam MP, Bick S, Mirzaa GM. Von Hippel-Lindau Syndrome. 1993. PMID: 20301636
- Lenders JW, Eisenhofer G, Mannelli M. Phaeochromocytoma. Lancet (London, England). 2005. PMID: 16112304
- Chou A, Toon C, Pickett J. von Hippel-Lindau syndrome. Frontiers of hormone research. 2013. PMID: 23652669
- Rinaldi L, Senatore E, Feliciello S. Kidney cancer: From tumor biology to innovative therapeutics. Biochimica et biophysica acta. Reviews on cancer. 2025. PMID: 39674419
- Neumann HP, Lips CJ, Hsia YE. Von Hippel-Lindau syndrome. Brain pathology (Zurich, Switzerland). 1995. PMID: 7670659
- Mikhail MI, Singh AK. Von Hippel-Lindau Syndrome (Archived). 2023. PMID: 29083737